Back to Browse Journals » Cancer Management and Research » Volume 1

Bortezomib in the management of multiple myeloma

Authors Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al

Published Date September 2009 Volume 2009:1 Pages 107—117

DOI http://dx.doi.org/10.2147/CMAR.S4555

Published 8 September 2009

Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G Richardson

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molecule proteasome inhibitor bortezomib occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.

Keywords: multiple myeloma, bortezomib, stem cell transplantation, peripheral neuropathy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

Paul Richardson, Constantine Mitsiades, Jacob Laubach, et al

Core Evidence 2009, 4:215-245

Published Date: 17 November 2009

Readers of this article also read:

Single event-related changes in cerebral oxygenated hemoglobin using word game in schizophrenia

Fujiki R, Morita K, Sato M, Yamashita Y, Kato Y, Ishii Y, Shoji Y, Uchimura N

Neuropsychiatric Disease and Treatment 2014, 10:2353-2360

Published Date: 11 December 2014

Corrigendum

Sailasuta N, Harris K, Tran T, Ross B

Neuropsychiatric Disease and Treatment 2011, 7:707-708

Published Date: 25 November 2011

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Central retinal artery occlusion resembling Purtscher-like retinopathy

Kurimoto T, Okamoto N, Oku H, Kanbara Y, Etomi T, Tonari M, Ikeda T

Clinical Ophthalmology 2011, 5:1083-1088

Published Date: 4 August 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

Evolving role of cetuximab in the treatment of colorectal cancer

Gunter Schuch, Sebastian Kobold, Carsten Bokemeyer

Cancer Management and Research 2009, 1:79-88

Published Date: 23 July 2009

Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222

Aminah Jatoi, Shauna L Hillman, Katie L Allen Ziegler, Philip J Stella, et al.

Cancer Management and Research 2009, 1:61-68

Published Date: 17 June 2009

Validation of the cell cycle G2 delay assay in assessing ionizing radiation sensitivity and breast cancer risk

Jeff W Hill, Kristina Tansavatdi, Kristin L Lockett, Glenn O Allen, et al.

Cancer Management and Research 2009, 1:39-48

Published Date: 30 April 2009

Treatment of postherpetic neuralgia: focus on pregabalin

Kimberly A Cappuzzo

Clinical Interventions in Aging 2009, 4:17-23

Published Date: 23 December 2008